FIELD: medicine.
SUBSTANCE: invention concerns bonds of the general formula , where t it is peer 0, 1 or 2; everyone R independently represents H, alkyl, alkenyl, alkinyl, halogenalkyl, cycloalkyl, -RaAy, -RaOR5; n it is peer O; R2 it is chosen from the group consisting from H, probably substituted alkyl, alkenyl, alkinyl, cycloalkyl, -RaAy,-RaOR5, and R2 is not an amine or an alkylamin, or it is not substituted by an amine or an alkylamin; R3 represents H, probably substituted alkyl, alkenyl, alkinyl, halogenalkyl, cycloalkyl, -RaAy, -RaOR5 where when p it is peer 0, R3 is not amine or an alkylamin, or it is not replaced by amine or an alkylamin; everyone R4 independently represents halogen, alkyl, alkenyl, alkinyl, halogenalkyl, cycloalkyl, cycloalkenyl, -Ay, -NHAy, -Het, -NHHet, -NR6R7, -RaNR6R7, -RaC(O)R10, -C(O)R10, -CO2R10, -RaCO2R10, -C(O)NR6R7, -C(O)Ay, -C(O)Het; m it is peer 0, 1 or 2; every R5 independently represents H, alkyl, alkenyl, alkinyl, cycloalkyl, -RaAy or -Ay; p it is peer 0 or 1; Y represents -NR10-, -C(O)NR10-, -NR10C(O)-, -C(O)-, -C(O)O-, -NR10C(O)N(R10)2-, X represents -N(R10)2, -RaN(R10)2, -AyN(R10)2, -RaAyN(R10)2, -AyRaN(R10)2, -RaAyRaN(R10)2, -Het, -RaHet, -HetN(R10)2, -RaHetN(R10)2, -HetRaN(R10)2, -RaHetRaN(R10)2, HetRaAy or HetRaHet, where, when p it is peer 0 then X is not -N(R10)2; everyone Ra independently represents probably replaced alkylene, cycloalkylene, alkenylene, cycloalkenylene or alkinilene; every R10 independently represents H, alkyl, cycloalkyl, alkenyl, alkinyl, cycloalkenyl, -racycloalkyl, -RaOH, -RaOR5, -RaNR6R7 or -RaHet; each of R6 and R7 is independently chosen from H, alkyl, cycloalkyl, alkenyl, alkinyl, cycloalkenyl, groups-racycloalkyl, -RaOH, -RaOR5, -Het, -RaHet; every Ay independently represents probably substituted aryl group; and every Het independently represents probably substituted 4, 5 either 6-termed heterocycle or eheteroaryl group where heteroatoms are chosen from N and O; to a pharmaceutical composition for treatment and HIV-infection preventive maintenance, to application of bonds formulas I, in medical product manufacturing, and also to ways of reception of bond of the formula I.
EFFECT: rising of efficiency of a composition and the method of treatment.
55 cl, 2 tbl, 185 ex
Title | Year | Author | Number |
---|---|---|---|
HETEROCYCLIC COMPOUNDS, PHARMACEUTICAL COMPOSITION CONTAINING THEREOF AND THEIR USING | 2001 |
|
RU2289581C2 |
HETEROCYCLIC COMPOUNDS MODULATING ACTIVITY OF CHEMOKINE RECEPTOR, THEIR USING AND PHARMACEUTICAL COMPOSITION CONTAINING THEREOF | 2001 |
|
RU2297413C2 |
TETRAHYDROQUINOLINE DERIVATIVES AND BASED PHARMACEUTICAL COMPOSITION FOR HIV INFECTION TREATMENT AND PREVENTION | 2005 |
|
RU2351592C2 |
PYRIDAZINE DERIVATIVES AS RORc MODULATORS | 2017 |
|
RU2757571C2 |
METHODS FOR PREPARING DERIVATIVES OF 1-[2-(BENZIMIDAZOL-1-YL)QUINOLIN-8-YL]PIPERIDIN-4-YLAMINE | 2004 |
|
RU2323214C2 |
PIPERIDINYL COMPOUNDS FOR SELECTIVE INTEGRINE BINDING | 2003 |
|
RU2333210C2 |
METHODS FOR PRODUCTION OF RACEMIC AMINOSUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE OR RACEMIC AMINOSUBSTITUTED 5,6,7,8-TETRAHYDROISOQUINOLINE, METHODS FOR SEPARATION AND RACEMIZATION THEREOF, METHODS FOR PRODUCTION OF KETOSUBSTITUTED 5,6,7,8-TETRAHYDROQUINOLINE OR KETOSUBSTITUTED 5,6,7,8-TETRAHYDROISOQUINOLINE, METHOD FOR PRODUCTION OF ENANTIOMER PF CONDENSED BYCYCLIC RING SUBSTITUTED WITH PRIMARY AMINE, 5,6,7,8-TETRAHYDROQUINOLINE DERIVATIVES | 2002 |
|
RU2308451C2 |
AVB6 INTEGRIN INHIBITORS | 2018 |
|
RU2769702C2 |
HETEROCYCLIC COMPOUNDS, THEIR USING AND PHARMACEUTICAL COMPOSITION FOR TREATMENT OF STATES MEDIATED BY CXCR4 AND CCR5 | 2001 |
|
RU2277092C2 |
COMPOUNDS WITH CONDENSED RINGS | 2019 |
|
RU2783414C2 |
Authors
Dates
2009-03-27—Published
2005-08-12—Filed